Welcome to our dedicated page for OSR Holdings SEC filings (Ticker: OSRH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OSR Holdings, Inc. (NASDAQ: OSRH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. OSR Holdings is a global healthcare holding company engaged through its subsidiaries in immuno-oncology, regenerative biologics, and medical device technologies, and its filings offer detailed information on corporate transactions, governance, financing arrangements, and listing status.
Investors can review Form 8-K current reports where OSR Holdings describes material events such as share exchange agreements, licensing term sheets, financing amendments, and notices from The Nasdaq Stock Market LLC. For example, 8-K filings outline the Share Exchange Agreement under which OSR Holdings Co., Ltd. will acquire all issued and outstanding shares of Woori IO Co., Ltd., making Woori IO a wholly owned subsidiary, and describe Woori IO’s non-invasive biosensing technology for glucose monitoring. Other 8-Ks detail Vaximm AG’s non-binding and binding term sheets with BCM Europe AG for potential global licensing of the VXM01 oral cancer immunotherapy platform, including exclusivity periods and proposed financial structures.
The company’s proxy materials, such as the Definitive Proxy Statement on Schedule DEF 14A, set out proposals for director elections, advisory votes on executive compensation, share-based incentive plans under the 2025 Omnibus Incentive Plan, and approvals under Nasdaq Listing Rule 5635(d) for potential issuances of common stock or related securities in excess of 20% of outstanding shares. These documents also confirm OSR Holdings’ status as an emerging growth company and describe its principal executive offices and meeting logistics.
Filings also include disclosures related to Nasdaq listing compliance, such as the Form 8-K describing receipt of a minimum bid price deficiency notice under Listing Rule 5550(a)(2), along with the company’s stated intention to monitor its share price and consider options to regain compliance. Additional 8-Ks cover amendments to a Note Purchase Agreement and Common Stock Purchase Warrant with White Lion Capital, LLC, clarifying exchange caps and shareholder approval requirements.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key terms, conditions, and implications for OSR Holdings’ capital structure and strategic direction. Users can quickly scan material agreements, governance proposals, and listing updates, and then drill down into the full-text filings for deeper analysis, including exhibits such as term sheets, annexes, and press releases incorporated by reference.
The preliminary proxy statement for OSR Holdings, Inc. (PRE 14A) sets four proposals for the annual meeting: elect seven directors to the board; approve, on a non-binding advisory basis, named executive officer compensation; adopt share-based incentive sub-plans under a 2025 Omnibus Incentive Plan including RSU and Option sub-plans; and approve, under Nasdaq Listing Rule 5635(d), the ability to issue in one or more non-public offerings shares (or convertible/exercisable securities) that may exceed 20% of outstanding common stock at a price determined as the lower of the Nasdaq Official Closing Price immediately preceding signing or the five-day average prior to signing.
The filing shows 6,300,000 shares remain available for issuance under the Omnibus Plan and lists certain individual beneficial holdings disclosed in the document, including Sang Hoon Kim: 84,020 and Gihyoun Bang: 47,367. The statement also lists director nominees and procedural sections such as voting, proxies and solicitation details.
OSR Holdings, Inc. (OSRH) completed a business combination in February 2025 and reported consolidated assets of $185.4 million and cash of $1.58 million as of June 30, 2025, up from $341,543 at December 31, 2024, including $1,219,888 received from the business combination. Intangible assets, principally patent technology, totaled $155.6 million and goodwill was $26.4 million.
Revenue from the medical-device distribution subsidiary increased to $1.14 million for the quarter, but gross profit fell sharply to $32,782 due to a supplier contract change and inventory returned under a consignment arrangement. Operating loss widened to $(5.23) million for the quarter and net loss for the six months was $(16.62) million, which included approximately $8.5 million of merger-related costs. Current liabilities rose to $15.86 million and a derivative liability of $630,603 was recorded. Recent disclosures include a July 2025 tokenization roadmap with BCM Europe AG and a signed term sheet to acquire Woori IO (noninvasive glucose monitoring), subject to due diligence and milestone-based share issuance.
OSR Holdings, Inc. (Nasdaq: OSRH) filed a Form 8-K to disclose that independent director Sang Hyun Kim resigned from the Board of Directors effective June 26 2025. The company states the resignation "was not the result of any dispute or disagreement" concerning its operations, policies, or practices. No other management changes, financial results, or strategic actions were reported.
- Event date: June 26 2025 (reported July 2 2025)
- Affected position: Independent director seat now vacant
- Reason given: Personal resignation, no disputes cited
No compensatory arrangements, replacement plans, or additional board changes were included in the filing.